Mizuho Securities Maintains Healthpeak Properties(DOC.US) With Buy Rating
Strategic Growth and Valuation Justify Buy Rating for Healthpeak Properties
Analysts Offer Insights on Real Estate Companies: VICI Properties (VICI) and Healthpeak Properties (DOC)
RBC Raises Price Target on Healthpeak Properties to $26 From $25
Baird Maintains Healthpeak Properties(DOC.US) With Buy Rating, Raises Target Price to $25
Healthpeak Properties Is Maintained at Outperform by Baird
Healthpeak Properties Analyst Ratings
Baird Maintains Healthpeak Properties(DOC.US) With Buy Rating, Cuts Target Price to $25
KeyBanc Maintains Healthpeak Properties(DOC.US) With Hold Rating
Mizuho Securities Maintains Healthpeak Properties(DOC.US) With Buy Rating
Evercore Maintains Healthpeak Properties(DOC.US) With Buy Rating, Maintains Target Price $26
Healthpeak Properties (DOC) Receives a Buy From Evercore ISI
Scotiabank Maintains Healthpeak Properties(DOC.US) With Buy Rating, Maintains Target Price $24
Analysts Offer Insights on Real Estate Companies: Healthpeak Properties (DOC) and Cousins Properties (CUZ)
Morgan Stanley Maintains Healthpeak Properties(DOC.US) With Hold Rating, Maintains Target Price $23.5
BMO Capital Maintains Healthpeak Properties(DOC.US) With Buy Rating, Raises Target Price to $26
Healthpeak Properties: Strong Q3 2024 Earnings and Positive Financial Outlook Justify Buy Rating
Healthpeak Properties Analyst Ratings
Deutsche Bank Upgrades Healthpeak Properties(DOC.US) to Buy Rating, Raises Target Price to $28
Morgan Stanley Maintains Healthpeak Properties(DOC.US) With Hold Rating, Maintains Target Price $23.5